You can read the Diaceutics Pharma Readiness for Personalized Medicine Report in more detail at the following link: http://www.diaceutics.com/pm-readiness-2015

Diaceutics PM Readiness 2015 report provides a snapshot of how

commercially ready pharma is for personalized medicine. It shows

how the competitive landscape has changed since its last report in

2010.

SUBJECTS

12 PHARMACOMPANIES EXAMINED

COMPANION DIAGNOSTICS

76

PERSONALIZED THERAPIES IN

PIPELINE

NO. of PM THERAPIES

IN PHASE 3

TARGET THERAPIES

MORE THERAPIES THAN

IN 2010

ARE NOW CLASSFIED AS

TARGETED THERAPIES

TIMESCALE

2014

2010TRACKS COMPETITIVE

CHANGES

FROM

2010-2014

DATA SETS

OVER8000DATA SETS

USED

WHICH COMPANIES HAVE DONE WELL?

*Disrupters - companies which have demonstrated the ability to competitively reshape therapy areas via personalized medicine;

Breakaway - companies that have made proactive investments positioning themselves to migrate operating models and corporate structure to

successfully commercialize targeted therapies; and

Followers - companies most likely to respond to the actions of others with little central PM management and little commercial experience with PM

therapies.

53therapies retrofitted

with biomarkers

7 therapies linked

to FDA Approved Cdx

launched

KEY HEADLINES BY NUMBERS

2X

PERSONALIZED THERAPIES ON THE

MARKET

% of PM THERAPIES

ON THE MARKET3X

ROCHE THE MOST CDX DEALS

2010-2014

THE HIGHEST % OF PM

ONCOLOGY THERAPIES

ANDWHICH ONCOLOGY PM THERAPIES HAVE

HAD THE HIGHEST SALES?

HERCEPTINRITUXAN

GLEEVAC

WHO IS COMMERICALLY READY FOR PERSONALIZED MEDICINE?

DISRUPTORS

BREAKAWAY

FOLLOWERS

JANSSEN

ROCHE

NOVARTIS

ASTRAZENECA

GSK

PFIZERBMS

BOEHRINGER INGELHEIM

MERCK

AMGEN

SANOFIELI LILLY

SANOFI THE HIGHEST % OF PM THERAPIES

IN PHASE III/REGISTRATION